218 related articles for article (PubMed ID: 16420976)
1. In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur?
Kleinschmidt SL; Munckhof WJ; Nimmo GR
Int J Antimicrob Agents; 2006 Feb; 27(2):168-70. PubMed ID: 16420976
[TBL] [Abstract][Full Text] [Related]
2. Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study.
Munckhof WJ; Kleinschmidt SL; Turnidge JD
Int J Antimicrob Agents; 2004 Dec; 24(6):605-8. PubMed ID: 15555885
[TBL] [Abstract][Full Text] [Related]
3. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
4. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
5. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
[TBL] [Abstract][Full Text] [Related]
6. An analysis of a community-acquired pathogen in a Kentucky community: methicillin-resistant Staphylococcus aureus.
Arnold FW; Wojda B
J Ky Med Assoc; 2005 May; 103(5):206-10. PubMed ID: 15918650
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus.
LaPlante KL; Rybak MJ; Amjad M; Kaatz GW
Pharmacotherapy; 2007 Jan; 27(1):3-10. PubMed ID: 17192156
[TBL] [Abstract][Full Text] [Related]
8. [Methicillin-resistant Staphylococcus aureus (MRSA) in the community].
Vonk AG; Vandenbroucke-Grauls CM
Ned Tijdschr Geneeskd; 2007 Feb; 151(7):401-7. PubMed ID: 17343138
[TBL] [Abstract][Full Text] [Related]
9. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.
Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F
J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
12. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.
Sakoulas G; Gold HS; Cohen RA; Venkataraman L; Moellering RC; Eliopoulos GM
J Antimicrob Chemother; 2006 Apr; 57(4):699-704. PubMed ID: 16464892
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.
Hussain FM; Boyle-Vavra S; Shete PB; Daum RS
J Infect Dis; 2002 Sep; 186(5):661-7. PubMed ID: 12195353
[TBL] [Abstract][Full Text] [Related]
14. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999].
Nashev D; Toshkova K; Gavrilova V
Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664
[TBL] [Abstract][Full Text] [Related]
15. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Lodise TP; Miller CD; Graves J; Evans A; Graffunder E; Helmecke M; Stellrecht K
J Antimicrob Chemother; 2008 Nov; 62(5):1138-41. PubMed ID: 18694905
[TBL] [Abstract][Full Text] [Related]
16. Community-acquired methicillin-resistant Staphylococcus aureus infections in children.
Kaplan SL
Semin Pediatr Infect Dis; 2006 Jul; 17(3):113-9. PubMed ID: 16934705
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of laboratory-generated vancomycin intermediate resistant Staphylococcus aureus strains.
Bhateja P; Purnapatre K; Dube S; Fatma T; Rattan A
Int J Antimicrob Agents; 2006 Mar; 27(3):201-11. PubMed ID: 16417988
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates.
Kotlus BS; Wymbs RA; Vellozzi EM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):726-9. PubMed ID: 17056356
[TBL] [Abstract][Full Text] [Related]
19. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
[TBL] [Abstract][Full Text] [Related]
20. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
